Xuanwu Hospital, Beijing

This study tested a drug called zanubrutinib in 6 adults with neuromyelitis optica spectrum disorder (NMOSD), a rare disease where the immune system attacks the nerves in the eyes and spine. The goal was to see if the drug could prevent relapses and reduce disability. The trial w…